SCYNEXIS Inc SCYX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $4.05
- Day Range
- $3.85–4.22
- 52-Week Range
- $3.68–10.48
- Bid/Ask
- $3.58 / $4.20
- Shares Outstanding
- 9.93M
- Market Cap
- $39.27M
- Volume/Avg
- 165,864 / 66,718
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.25
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
- Website
- https://www.scynexis.com
Valuation
|
Metric
|
SCYX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.76 |
Price/Sales | 1.25 |
Price/Cash Flow | — |
Price/Earnings
SCYX
Financial Strength
|
Metric
|
SCYX
|
|---|---|
Quick Ratio | 3.73 |
Current Ratio | 3.94 |
Interest Coverage | — |
Quick Ratio
SCYX
Profitability
|
Metric
|
SCYX
|
|---|---|
Return on Assets (Normalized) | −29.63% |
Return on Equity (Normalized) | −42.20% |
Return on Invested Capital (Normalized) | −44.24% |
Return on Assets
SCYX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|#t>d!fX@ | LOCK|Db?W? | $67B | |||
| Haleon PLC ADR
HLN
| LOCK|%J>k$c# | LOCK|sH | $44B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|n%><ZD! | LOCK|r$@g# | $37B | |||
| Zoetis Inc Class A
ZTS
| LOCK|JPmsl$^ | LOCK|%@ | $32B | |||
| Viatris Inc
VTRS
| LOCK|g^LcJnX | LOCK|Rq | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|Df | LOCK|J?< | $13B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|hJ@Stb! | LOCK|%B | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|X@#BVS | LOCK|^W | $8B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|ptQg$$H | LOCK|zZNF | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|<PP#Gw | LOCK|Qj | $1B |
United States